These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 27687979)

  • 1. Mouse models in oncoimmunology.
    Zitvogel L; Pitt JM; Daillère R; Smyth MJ; Kroemer G
    Nat Rev Cancer; 2016 Dec; 16(12):759-773. PubMed ID: 27687979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Applications of Patient-Derived Xenograft Models in Humanized Mice for Oncology and Immune-Oncology Drug Discovery.
    Verma B; Ritchie M; Mancini M
    Curr Protoc Pharmacol; 2017 Sep; 78():14.41.1-14.41.12. PubMed ID: 28892144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological aspects of cancer chemotherapy.
    Zitvogel L; Apetoh L; Ghiringhelli F; Kroemer G
    Nat Rev Immunol; 2008 Jan; 8(1):59-73. PubMed ID: 18097448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orthotopic Mouse Models of Urothelial Cancer.
    Jäger W; Moskalev I; Raven P; Goriki A; Bidnur S; Black PC
    Methods Mol Biol; 2018; 1655():177-197. PubMed ID: 28889387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy.
    Wege AK
    BioDrugs; 2018 Jun; 32(3):245-266. PubMed ID: 29589229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconstituting the Human Immune System.
    Cancer Discov; 2016 Aug; 6(8):812. PubMed ID: 27406744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically engineered models have advantages over xenografts for preclinical studies.
    Becher OJ; Holland EC
    Cancer Res; 2006 Apr; 66(7):3355-8, discussion 3358-9. PubMed ID: 16585152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
    Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
    Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.
    Zitvogel L; Galluzzi L; Smyth MJ; Kroemer G
    Immunity; 2013 Jul; 39(1):74-88. PubMed ID: 23890065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.
    Hansen K; Khanna C
    Eur J Cancer; 2004 Apr; 40(6):858-80. PubMed ID: 15120042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
    Ruggeri BA; Camp F; Miknyoczki S
    Biochem Pharmacol; 2014 Jan; 87(1):150-61. PubMed ID: 23817077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
    Olive KP; Tuveson DA
    Clin Cancer Res; 2006 Sep; 12(18):5277-87. PubMed ID: 17000660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tg.AC genetically altered mouse: assay working group overview of available data.
    Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
    Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bub1 up-regulation and hyperphosphorylation promote malignant transformation in SV40 tag-induced transgenic mouse models.
    Guo C; Wu G; Chin JL; Bauman G; Moussa M; Wang F; Greenberg NM; Taylor SS; Xuan JW
    Mol Cancer Res; 2006 Dec; 4(12):957-69. PubMed ID: 17189386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.
    Lu S; Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Li Z; Wu JD
    Clin Cancer Res; 2015 Nov; 21(21):4819-30. PubMed ID: 26106076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically modified mouse models for biomarker discovery and preclinical drug testing.
    Kucherlapati R
    Clin Cancer Res; 2012 Feb; 18(3):625-30. PubMed ID: 22298895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canine cancer immunotherapy studies: linking mouse and human.
    Park JS; Withers SS; Modiano JF; Kent MS; Chen M; Luna JI; Culp WTN; Sparger EE; Rebhun RB; Monjazeb AM; Murphy WJ; Canter RJ
    J Immunother Cancer; 2016; 4():97. PubMed ID: 28031824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models.
    van Steeg H; de Vries A; van Oostrom CTh ; van Benthem J; Beems RB; van Kreijl CF
    Toxicol Pathol; 2001; 29 Suppl():109-16. PubMed ID: 11695546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological responses can have both pro- and antitumour effects: implications for immunotherapy.
    Stewart TJ; Greeneltch KM; Lutsiak ME; Abrams SI
    Expert Rev Mol Med; 2007 Feb; 9(4):1-20. PubMed ID: 17284328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.